JP2017535612A5 - - Google Patents

Download PDF

Info

Publication number
JP2017535612A5
JP2017535612A5 JP2017545857A JP2017545857A JP2017535612A5 JP 2017535612 A5 JP2017535612 A5 JP 2017535612A5 JP 2017545857 A JP2017545857 A JP 2017545857A JP 2017545857 A JP2017545857 A JP 2017545857A JP 2017535612 A5 JP2017535612 A5 JP 2017535612A5
Authority
JP
Japan
Prior art keywords
nasal
disorder
preparation
riluzole
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017545857A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017535612A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/061106 external-priority patent/WO2016081466A1/en
Publication of JP2017535612A publication Critical patent/JP2017535612A/ja
Publication of JP2017535612A5 publication Critical patent/JP2017535612A5/ja
Pending legal-status Critical Current

Links

JP2017545857A 2014-11-21 2015-11-17 リルゾールの舌下投与 Pending JP2017535612A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462083068P 2014-11-21 2014-11-21
US62/083,068 2014-11-21
PCT/US2015/061106 WO2016081466A1 (en) 2014-11-21 2015-11-17 Sublingual administration of riluzole

Publications (2)

Publication Number Publication Date
JP2017535612A JP2017535612A (ja) 2017-11-30
JP2017535612A5 true JP2017535612A5 (cg-RX-API-DMAC7.html) 2018-11-01

Family

ID=55077617

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017545857A Pending JP2017535612A (ja) 2014-11-21 2015-11-17 リルゾールの舌下投与

Country Status (14)

Country Link
US (1) US20180153862A1 (cg-RX-API-DMAC7.html)
EP (1) EP3220890A1 (cg-RX-API-DMAC7.html)
JP (1) JP2017535612A (cg-RX-API-DMAC7.html)
KR (1) KR20170137030A (cg-RX-API-DMAC7.html)
CN (1) CN107735077A (cg-RX-API-DMAC7.html)
AU (1) AU2015350142A1 (cg-RX-API-DMAC7.html)
BR (1) BR112017010440A2 (cg-RX-API-DMAC7.html)
CA (1) CA2967659A1 (cg-RX-API-DMAC7.html)
EA (1) EA201791110A1 (cg-RX-API-DMAC7.html)
IL (1) IL252283A0 (cg-RX-API-DMAC7.html)
MX (1) MX2017006454A (cg-RX-API-DMAC7.html)
PH (1) PH12017500933A1 (cg-RX-API-DMAC7.html)
SG (1) SG11201703897SA (cg-RX-API-DMAC7.html)
WO (1) WO2016081466A1 (cg-RX-API-DMAC7.html)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9925282B2 (en) 2009-01-29 2018-03-27 The General Hospital Corporation Cromolyn derivatives and related methods of imaging and treatment
US10188757B2 (en) 2013-10-22 2019-01-29 The General Hospital Corporation Cromolyn derivatives and related methods of imaging and treatment
SG11201703896QA (en) 2014-11-21 2017-06-29 Biohaven Pharm Holding Co Ltd Sublingual formulation of riluzole
US9899038B2 (en) 2016-06-30 2018-02-20 Karen Elaine Khaleghi Electronic notebook system
JP2019524865A (ja) 2016-08-31 2019-09-05 ザ ジェネラル ホスピタル コーポレイション 神経変性疾患と関連する神経炎症におけるマクロファージ/ミクログリア
EP3512509A1 (en) * 2016-09-15 2019-07-24 Skintech Life Science Limited Sublingual or buccal administration of dim for treatment of skin diseases
MX2020008680A (es) * 2018-02-21 2020-09-25 Ai Therapeutics Inc Terapia de combinacion con apilimod y agentes glutamatergicos.
US10235998B1 (en) * 2018-02-28 2019-03-19 Karen Elaine Khaleghi Health monitoring system and appliance
AU2019251191A1 (en) * 2018-04-09 2020-10-29 The General Hospital Corporation Combination therapies for the treatment of amyotropic lateral sclerosis and related disorders
CN112203692A (zh) * 2018-05-27 2021-01-08 拜尔哈文制药股份有限公司 利鲁唑口腔崩解片用于治疗疾病的用途
AU2019322889A1 (en) * 2018-08-16 2021-03-04 Biohaven Therapeutics Ltd. Use of riluzole oral disintigrating tablets for treating diseases
MX2021006869A (es) 2018-12-10 2021-07-02 Massachusetts Gen Hospital Esteres de cromolin y usos de los mismos.
US10559307B1 (en) 2019-02-13 2020-02-11 Karen Elaine Khaleghi Impaired operator detection and interlock apparatus
EP4132507A4 (en) 2020-04-06 2024-05-15 The General Hospital Corporation METHODS FOR TREATING CORONAVIRUS-INDUCED INFLAMMATORY CONDITIONS

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2492258A1 (fr) * 1980-10-17 1982-04-23 Pharmindustrie Nouveau medicament a base d'amino-2 trifluoromethoxy-6 benzothiazole
US5837287A (en) * 1994-10-28 1998-11-17 R P Scherer Corporation Process for preparing solid pharmaceutical dosage forms
FR2787028B1 (fr) * 1998-12-15 2002-10-18 Aventis Pharma Sa Utilisation du riluzole dans le traitement des traumatismes acoustiques
NZ515685A (en) * 1999-06-04 2002-12-20 Vereniging Voor Christelijk Wetenschappelijk Onderwijs Use of riluzole for the treatment of multiple sclerosis
US20040077591A1 (en) * 2002-03-28 2004-04-22 The Brigham And Women's Hospital, Inc. Histone deacetylase inhibitors for the treatment of multiple sclerosis, amyotrophic lateral sclerosis and Alzheimer's Disease
GB0304636D0 (en) * 2003-02-28 2003-04-02 Britannia Pharmaceuticals Ltd Pharmaceutical composition for nasal delivery
EP2228054A1 (en) * 2009-03-13 2010-09-15 ITALFARMACO S.p.A. Riluzole aqueous suspensions
JP2011093849A (ja) * 2009-10-30 2011-05-12 Kissei Pharmaceutical Co Ltd トラニラストの易溶性粉末吸入製剤
US9241933B2 (en) * 2011-03-01 2016-01-26 Pharnext Compositions for treating amyotrophic lateral sclerosis
PH12014500094A1 (en) * 2011-07-13 2014-03-17 Cytokinetics Inc Combination als therapy
CA3075331A1 (en) * 2012-03-01 2013-09-06 Pharnext New compositions for treating amyotrophic lateral sclerosis

Similar Documents

Publication Publication Date Title
JP2017535612A5 (cg-RX-API-DMAC7.html)
JP2017535613A5 (cg-RX-API-DMAC7.html)
Jee et al. Impact of sleep disorder as a risk factor for dementia in men and women
Mischoulon et al. Role of S-adenosyl-L-methionine in the treatment of depression: a review of the evidence
MacFarlane et al. Hypnotics in insomnia: the experience of zolpidem
IL191311A (en) Transdermal therapeutic system and its use in the preparation of drugs for the prevention, treatment or delay of the progression of Alzheimer's disease, Parkinson's disease-related dementia and symptoms of traumatic brain injury
RU2013154699A (ru) Сцилло-инозитол для применения в лечении поведенческих и психических расстройств
Laura et al. The effects of music therapy on anxiety and depression
JP2017526693A5 (cg-RX-API-DMAC7.html)
Winkelman et al. Current patterns and future directions in the treatment of insomnia
CN104127730A (zh) 一种治疗神经衰弱的中药及其制备方法
Shinde et al. Homoeopathy for post COVID 19 illnesses: A case series
Kim et al. A case report of ptosis patient diagnosed as idiopathic oculomotor nerve palsy
Im et al. Management of sleep disorders in stroke
CN101623404B (zh) 一种治疗原发性三叉神经痛的中药组合物
Jung et al. The Effect of Laughter Therapy on Sleep in the Community-dwelling Elderly.
CN103656380A (zh) 一种治疗帕金森病的药物
CN110680880A (zh) 一种治疗肝阳上亢型失眠的中药组合物及其用途
CN106177761B (zh) 一种抗抑郁的中药组方及其制品
Hajilou Review of Different Applications of Sildenafil with the Focus on its Role in Alzheimer's Disease
D’yakonov et al. Comparative studies of the efficacy of combinations of SSRI antidepressants and antipsychotics in the treatment of recurrent depressive disorder
Kalko et al. Potential risks and pharmacological safety features of hypnotics. Music therapy as a non-drug way to improve sleep quality
Bakhrushina et al. THE RELEVANCE OF THE PHARMACEUTICAL DEVELOPMENT OF THE NEW DOSAGE FORMS OF HOPANTENIC ACID
ES2969657T3 (es) Tratamiento de trastorno de síndrome postraumático
CN102552423B (zh) 一种治疗偏头痛的药物组合物